Patents Examined by Susanna Moore
-
Patent number: 12291534Abstract: The present invention relates to a compound of formula I or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an ester, an optical isomer or a prodrug thereof, a pharmaceutical composition comprising the compound of formula I, and use of the compound, as a Bruton's tyrosine kinase inhibitor with high selectivity for BTK(C481S) mutant, in the manufacture of a medicament for preventing or treating a heteroimmune disease, an autoimmune disease or a cancer.Type: GrantFiled: July 5, 2019Date of Patent: May 6, 2025Assignee: TRANSTHERA SCIENCES (NANJING), INC.Inventor: Rongyao Chen
-
Patent number: 12286429Abstract: The present invention is directed to 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof The present invention is also directed to pharmaceutical compositions containing such compounds and the use of such compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.Type: GrantFiled: July 21, 2022Date of Patent: April 29, 2025Assignee: Janssen Pharmaceutica NVInventors: Guozhang Xu, Mark J. Macielag
-
Patent number: 12285488Abstract: Disclosed are stable dosage forms for oral administration of active pharmaceutical ingredients in which any unpleasant taste sensation, caused by release of the active pharmaceutical ingredient and/or of the excipients in the oral and pharyngeal cavity of the patient, is masked by the use of theobromine-free cocoa.Type: GrantFiled: March 1, 2018Date of Patent: April 29, 2025Assignee: LTS Lohmann Therapie-Systeme AGInventors: Thomas Hille, Gabriel Wauer, Frank Seibertz
-
Patent number: 12286440Abstract: An object of the present invention is to provide a compound and a pharmaceutical composition which exhibit strong antibacterial activity against Gram-negative bacteria and drug-resistant Gram-negative bacteria. A compound represented by General Formula [1](the reference signs in Formula have the same definitions as those described in the present specification) or a salt thereof has strong antibacterial activity against Gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa, and the pharmaceutical composition containing the compound or a salt thereof is useful as an antibacterial agent.Type: GrantFiled: October 5, 2020Date of Patent: April 29, 2025Assignee: FUJIFILM CorporationInventors: Muneo Shoji, Kentaro Furuya, Kei Matsuura, Tomofumi Nakae
-
Patent number: 12281073Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.Type: GrantFiled: July 5, 2023Date of Patent: April 22, 2025Assignee: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
-
Patent number: 12275739Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.Type: GrantFiled: November 6, 2023Date of Patent: April 15, 2025Assignee: BIOMEA FUSION, INC.Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
-
Patent number: 12275728Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.Type: GrantFiled: May 24, 2024Date of Patent: April 15, 2025Assignee: BIOGEN MA INC.Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
-
Patent number: 12269828Abstract: Described herein are cyclic amide-containing pyridyl-xanthines of formula I and pharmaceutical compositions thereof that are useful as antagonists of A2B adenosine receptors.Type: GrantFiled: October 16, 2023Date of Patent: April 8, 2025Assignee: Adovate, LLCInventor: Robert D Thompson
-
Patent number: 12268667Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.Type: GrantFiled: May 3, 2022Date of Patent: April 8, 2025Assignee: Incyte CorporationInventors: Paul Smith, Kurt Andrew Brown
-
Patent number: 12258340Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising the same. The compounds and compositions are useful as modulators of monoacylglycerol lipase (MAGL). Furthermore, the compounds and compositions are useful for the treatment of pain.Type: GrantFiled: March 16, 2023Date of Patent: March 25, 2025Assignee: H. LUNDBECK A/SInventors: Cheryl A. Grice, John J. M. Wiener, Olivia D. Weber, Katharine K. Duncan
-
Patent number: 12258354Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.Type: GrantFiled: June 29, 2022Date of Patent: March 25, 2025Assignee: IDEAYA Biosciences, Inc.Inventors: Muzaffar Alam, Hilary Plake Beck, Michael Patrick Dillon, Marcos Gonzalez-Lopez, James Clifford Sutton, Jr.
-
Patent number: 12258370Abstract: The present disclosure relates to Betulastatin compounds, pharmaceutical compositions and kits comprising such compounds, and methods for using such compounds or pharmaceutical compositions.Type: GrantFiled: February 8, 2023Date of Patent: March 25, 2025Assignee: Arizona Board of Regents on behalf of Arizona State UniversityInventors: George R. Pettit, Noeleen Melody
-
Patent number: 12252495Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).Type: GrantFiled: August 4, 2023Date of Patent: March 18, 2025Assignee: ASTRAZENECA ABInventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
-
Patent number: 12252460Abstract: The present invention relates to a novel crystal modification of N-(aminoiminomethyl)-2-aminoacetic acid, crystal mixtures, and a process for preparing said crystal modification and said crystal mixtures.Type: GrantFiled: June 25, 2020Date of Patent: March 18, 2025Assignee: Alzchem Trostberg GmbHInventors: Thomas Güthner, Franz Thalhammer, Jürgen Sans
-
Patent number: 12247029Abstract: Compounds of the following formula: having defined substituents. The compounds can inhibit class II phosphoinositide 3-kinase (PI3K) signaling and are useful for the treatment of a medical condition associated with defective PI3K signaling, such as myopathy, cancer, diabetes, thrombosis or cardiovascular disease.Type: GrantFiled: June 7, 2019Date of Patent: March 11, 2025Assignee: Forschungsverbund Berlin e.V.Inventors: Wen-Ting Lo, Hassane Belabed, Volker Haucke, Marc Nazare, Murat Kucukdisli
-
Patent number: 12240867Abstract: Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.Type: GrantFiled: December 13, 2019Date of Patent: March 4, 2025Assignee: Merck Sharp & Dohme LLCInventors: Abdelghani Abe Achab, Matthew L. Childers, Jared N. Cumming, Symon Gathiaka, Charles A. Lesburg, Derun Li, Min Lu, Matthew J. Mitcheltree, Anandan Palani, Rachel L. Palte, Hongjun Zhang
-
Patent number: 12239632Abstract: Provided are allyl tryptamines, such as asymmetric allyl tryptamines. In some embodiments, such compounds modulate the activity of monoamine receptors and/or monoamine transporters. Also provided are methods for the preparation of allyl tryptamines and pharmaceutical compositions thereof. Methods of using the allyl tryptamines, alone or in combination with other therapeutic agents, are provided. In some embodiments, allyl tryptamines are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders, or are used for the improvement of mental health or functioning.Type: GrantFiled: March 4, 2024Date of Patent: March 4, 2025Assignee: Alexander Shulgin Research Institute, Inc.Inventors: Paul F. Daley, Nicholas V. Cozzi, Wyeth B. Callaway
-
Patent number: 12240829Abstract: The disclosure relates to Prostnglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.Type: GrantFiled: March 19, 2020Date of Patent: March 4, 2025Assignee: Emory UniversityInventors: Thota Ganesh, Raymond J. Dingledine, Radhika Amaradahi, Shabber Mohammed
-
Patent number: 12227521Abstract: The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.Type: GrantFiled: June 12, 2020Date of Patent: February 18, 2025Assignee: Nxera Pharma UK LimitedInventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield
-
Patent number: 12227520Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: October 28, 2022Date of Patent: February 18, 2025Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang